PPARα, but not PPARγ, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia-Reference-Cited by-同舟云学术

PPARα, but not PPARγ, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia

Published:2005-09 Issue:9 Volume:25 Page:1897-1902
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Hennuyer Nathalie¹,Tailleux Anne¹,Torpier Gérard¹,Mezdour Hafid¹,Fruchart Jean-Charles¹,Staels Bart¹,Fiévet Catherine¹

Affiliation:

1. From INSERM U545 (N.H., A.T., G.T., J.-C.F., B.S., C.F.), Département d’Athérosclérose, Institut Pasteur de Lille, France; Faculté de Pharmacie de Lille (A.T., J.-C.F., B.S.), Université de Lille 2, France; Laboratoire de Génétique Expérimentale (H.M.), Institut Pasteur de Lille, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference50 articles.

1. Peroxisome proliterator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

2. Clinical interest of PPARs ligands

3. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

4. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α;Molecular and Cellular Biochemistry;2023-05-12

2. Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease;Medicinal Research Reviews;2023-04-29

3. PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases;Frontiers in Endocrinology;2022-12-16

4. Network Pharmacology-Based Exploration of the Therapeutic Mechanisms of Cordyceps cicadae in Renal Ischemia/Reperfusion;Annals of Transplantation;2022-08-26

5. Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARα/γ partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and improves glucose tolerance in diet-induced obese mice;Bioorganic Chemistry;2022-03